Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

This publication has 14 references indexed in Scilit:

• Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
  Journal of Clinical Oncology, 1994
• Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant
  Cancer Immunology, Immunotherapy, 1993
• Active Immunization of Human Ovarian Cancer Patients Against a Common Carcinoma (Thomsen-Friedenreich) Determinant Using a Synthetic Carbohydrate Antigen
  Journal of Immunotherapy, 1992
• Rational Immunotherapy with Interleukin 2
  Nature Biotechnology, 1992
• Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats
  Vaccine, 1991
• A Randomized, Prospective Field Trial of a Conjugate Vaccine in the Protection of Infants and Young Children against InvasiveHaemophilus influenzaeType b Disease
  New England Journal of Medicine, 1990
• The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.
  Journal of Experimental Medicine, 1989
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines
  Cancer, 1985
• A dot-immunobinding assay for monoclonal and other antibodies
  Analytical Biochemistry, 1982